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A B S T R A C T
Acromegaly is a disease characterized by overproduction of growth hormone (GH). As a consequence of ex-
cessive GH secretion, circulating insulin-like growth factor-I (IGF-I) is elevated in active (untreated) acromegaly.
IGF-I is often used as a marker of disease activity and growth hormone status in acromegaly. Although IGF-I can
directly improve insulin sensitivity and glucose uptake in muscles, the excessive GH secretion in active acro-
megaly frequently leads to insulin resistance, glucose intolerance and even diabetes. In this review evidence will
be discussed that in active acromegaly chronically elevated IGF-I, insulin and soluble Klotho (S-Klotho) levels
play a pathophysiological role in the development of IGF-I receptor (IGF-IR) resistance. It is postulated that as
soon as circulating IGF-I, insulin and S-Klotho rise above a certain level the IGF-IR becomes relatively resistant to
actions of IGF-I. The development of a degree of IGF-IR resistance for metabolic actions may help to explain why
in active acromegaly diabetogenic effects of GH predominate and are not completely counteracted and neu-
tralized by elevated circulating levels of IGF-I. Further studies are necessary in order to support this hypothesis.
1. The GH-IGF-I axis in healthy subjects
In healthy subjects GH is released from somatotroph cells of the
anterior pituitary in a pulsatile fashion and activates the growth hor-
mone receptor (GHR) which is present at the cellular surface of target
tissues such as liver, muscle, adipose tissue, bone and kidney [36].
Release of GH is primarily regulated by growth hormone-releasing
hormone (GHRH; positive regulation), and somatostatin (negative
regulation) [36]. GH produced by the pituitary is the main regulator of
circulating insulin-like growth factor-I (IGF-I), which is particularly
produced by the liver [36,56]. A complicated system of short and long
feedback loops negatively regulates GH secretion in the healthy state
[36] (Fig. 1). It has been found that IGF-I itself might exert negative
feedback on GH secretion at the level of the hypothalamus and at
anterior pituitary [5,7] (Fig. 1). Pituitary cells contain specific receptors
for IGF-I [45]. IGF-I inhibits basal and GHRH-stimulated GH release
from cultured pituitary cells after 24 h of incubation [5]. Furthermore,
IGF-I stimulates the release of somatostatin from hypothalamic tissue
[5]. GH signaling is initiated by binding of GH to the GHR. One GH
molecule binds to two GHR molecules that exist as preformed homo-
dimers. After GH binding to the GHR, the intracellular domains of the
GHR dimer undergo rotation, which brings together the two in-
tracellular domains of the GHR [14]. A number of signaling proteins
and pathways activated by GH have been identified, including Janus
Kinases (JAKs), signal transducers and activators of transcription
(Stats), the mitogen activated protein kinase (MAPK) pathway, and the
phosphatidylinositol 3′-kinase (PI3K) pathway [33]. Although these
signal transduction pathways have been well characterized, the manner
by which GH activates these pathways and the downstream signals
induced by these pathways are not completely understood [33]. The
suppressor of cytokine signaling (SOCS) family of proteins plays an
important role in the negative regulation of GH signaling [33]. Other
important mechanisms whereby GH signaling is thought to be nega-
tively regulated is through protein tyrosine phosphatases (PTPs) and
ubiquitin-dependent GHR endocytosis [33]. Precise regulation of GH
signaling is important for the proper maintenance of body growth and
metabolism.
2. The IGF-I receptor and IGF-I receptor resistance
The IGF-IR is a heterotetrametric transmembrane protein composed
of two α and two β subunits. Binding of IGF-I to the alpha subunit of the
IGF-IR is followed by autophosphorylation of tyrosine residues on one β
subunit. The activated receptor recruits then phosphorylated in-
tracellularly substrates as the insulin receptor substrate proteins (IRSs)
and SH2-containing collagen-related proteins (SHC). Tyrosine phos-
phorylation of the IRSs in turn activates then the phosphatidylinositol
3-kinase (PI3K-Akt) pathway, which is predominantly involved in me-
tabolic actions (Fig. 2). Tyrosine phosphorylation of SHC induces
downstream signaling activation through the Ras/Raf/MEK/Erk
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pathway which is predominantly involved in mitogenic (growth-pro-
moting) actions (Fig. 2).
IGF-IR resistance has been previously reported in a variety of clin-
ical conditions. Some rare conditions are associated with genetic IGF-I
resistance [24]. Disease states such as diabetes, severe insulin re-
sistance, chronic renal insufficiency and HIV infection may cause ac-
quired IGF-IR resistance [24]. Acquired IGF-IR resistance may present
at the pre-receptor level through decreased bioavailability of IGF-I (for
example by circulating inhibitors of IGF-I action) [24]. It is also possible
that IGF-IR resistance is caused by defects of the IGF-IR self (by de-
creased number and/or affinity for IGF-I) or by post-receptor defects in
the intracellular signaling pathways of the IGF-IR [24]. IGF-IR re-
sistance may have different effects in various cells and organs, de-
pending on the cell-predominant enzymatic machinery. In addition, in
the setting of resistance by defects of the IGF-IR self, one would expect
that circulating IGF-I levels are elevated if classical negative feedback
regulation is operative [24].
3. Metabolic effects of growth hormone and insulin-like growth
factor-I
Metabolic effects of GH and IGF-I are essentially different. Whereas
GH leads to a decreased glucose uptake, elevated insulin secretion,
reduced insulin sensitivity and an increased lipolysis, IGF-I leads to an
increased glucose uptake, a reduced insulin secretion, enhanced insulin
sensitivity and neutral effects on lipolysis (Table 1). In healthy subjects
metabolic effects of GH and IGF-I are well in balance whereas in active
(untreated) acromegaly insulin antagonistic and diabetogenic effects of
GH on glucose metabolism predominate over IGF-I (Table 2). As a direct
consequence active acromegaly eventually may progress to impaired
glucose tolerance and diabetes by inducing a decreased glucose uptake
and an increased glycogenolysis and gluconeogenesis (Table 2).
4. Growth hormone, total IGF-I and acromegaly
Acromegaly is a disease characterized by overproduction of GH
which is most commonly due to a pituitary adenoma. In active acro-
megaly, cellular responses elicited by high GH levels overwhelm in-
tracellular mechanisms attenuating GH signaling [33,38]. Due to ex-
cessive GH secretion, circulating (immunoreactive) IGF-I
concentrations are elevated in active acromegaly [2]. Diagnosis of ac-
romegaly requires elevated circulating total IGF-I concentrations [47].
At present measurement of circulating total IGF-I concentrations is
considered the most sensitive and specific test to diagnose acromegaly.
In addition, total IGF-I concentrations are used as a marker of disease
activity and GH status. It is further used to judge the effectiveness of
therapeutic intervention [6]. However, measurement of total IGF-I does
not always seem to adequately reflect disease activity of active acro-
megaly [27]. This has been explained, at least partly, by the fact that
GH levels of 80–100 micrograms/L maximally activate IGF-I production
in humans and that higher GH levels in general do not further increase
in IGF-I production [32]. Another reason may be that in contrast to IGF-
I bioactivity measured by the insulin-like growth factor-I receptor ki-
nase activation assay (IGF-IR KIRA assay) total IGF-I levels measured by
immunoassays do not produce reliable information about modulating
effects of insulin-like growth factor binding proteins (IGFBPs) or IGFBP-
proteases on IGF-IR stimulating activity [26]. Furthermore, it could be
that there is a degree of IGF-IR resistance in active acromegaly (see
below).
5. Is acromegaly also a condition with acquired IGF-IR resistance?
In healthy subjects, as above discussed, IGF-I synthesis is stimulated
by GH and an increase in circulating IGF-I plays a central role in the
negative feedback regulation of GH secretion. Previously it has been
found that IGF-I itself might exert negative feedback on GH secretion at
the level of the hypothalamus and at anterior pituitary [5,7] (Fig. 3).
Concentrations of IGF-I in blood are determined- like many other cir-
culating hormones- by a balance between IGF-I secretion into the cir-
culation on the one hand and disappearance and breakdown of IGF-I
from the circulation on the other hand. It has been further reported that
in active acromegaly, compared to normal subjects, the amount of
circulating free/unbound IGF-I is higher [4,54]. Continuous exposure to
elevated hormone levels may cause a reduction in the number of re-
ceptors by promoting internalization as well as degradation of hormone
occupied receptors [50]. When a hormone stimulates its target cell,
simultaneously by negative feedback, it may reset the responsiveness of
the target cell to subsequent doses of hormone, resulting in a functional
hormone resistance [25,50]. Desensitization, the ability of a stimula-
tory ligand to reset the responsiveness of its target cells to its stimu-
lating actions is widespread [50]. For example, patients with type 2
diabetes with continuous exposure to elevated insulin levels develop a
degree of insulin resistance [35]. In this respect IGF-I and the IGF-IR
may show similarities to insulin and the insulin receptor: thus in active
acromegaly chronic exposure to elevated IGF-I levels may reset re-
sponsiveness of the IGF-IR and induce a degree of IGF-IR resistance.
Indeed, it has been found that chronic and prolonged stimulation with
IGF-I may induce functional IGF-IR resistance in vitro through a ne-
gative feedback loop [20]. In the setting of IGF-IR resistance in the
pituitary/hypothalamus, negative feedback by IGF-I on the pituitary
Fig. 1. The regulation of the GH-IGF-I axis. Growth Hormone Releasing
Hormone (GHRH) released by the hypothalamus stimulates Growth Hormone
(GH) in the pituitary gland. GH secretion by the pituitary is the primary reg-
ulator of insulin-like growth factor-I (IGF-I) production in the liver. IGF-I pro-
duced in the liver inhibits GH release via negative feedback on the pituitary and
via stimulation of somatostatin release in the hypothalamus. There is also direct
negative feedback by which GH stimulates hypothalamic somatostatin release.
Green: positive feedback; Red: negative feedback. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web
version of this article.)
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gland and hypothalamus would be ineffective, resulting in elevated GH
levels and, subsequently, further elevation of IGF-I levels [24].
In this paper we discuss the possibility that in (untreated) active
acromegaly chronically elevated IGF-I, insulin and S-Klotho levels in-
duce a degree of IGF-IR resistance: we hypothesize that as soon as
circulating IGF-I, insulin and S-Klotho levels rise above a certain level
(desensitization threshold), the IGF-IR becomes functionally resistant to
actions of IGF-I. When this hypothesis is correct, elevated circulating
IGF-I, insulin and S-Klotho levels may be drivers of (acquired) IGF-IR
resistance in active acromegaly. In the paragraphs that follow, I will
present further data and arguments to support this hypothesis.
6. Arguments for IGF-IR resistance in acromegaly
6.1. IGF-I and IGF-IR expression
In several animal models it has been found that IGF-IR expression in
muscle is negatively correlated to IGF-I levels, at least at the mRNA
level: bGH giant mice are mice with transgenic overexpression of bo-
vine GH. They showed twofold higher GH levels as well as high hepatic
IGF-I expression and serum IGF-I levels relative to controls but low
mRNA expression of the IGF-IR [42]. In contrast, dwarf GHR −/−
mice, mice which lack the GHR showed the opposite picture: the di-
minished GH signaling led to very low IGF-I levels and increases ex-
pression of the IGF-IR [42]. Furthermore, GHR and IGF-IR mRNA ex-
pression measured by real-time RT-PCR was significantly lower in
human somatotroph tumors of acromegaly patients than in normal pi-
tuitary tissue [28]. In addition, immunostaining showed that the re-
duced expression of mRNA for both the IGF-R in somatotroph tumors
was also reflected in lower protein expression of the IGF-IR [28]. Di-
minution of IGF-IR auto phosphorylation following chronic stimulation
by high IGF-I levels may be a mechanism that enables the body to avoid
overstimulation by IGF-I [20]. It has been reported that high IGF-I itself
rapidly downregulates the IGF-IR expression following binding to the
IGF-IR [11,48]. Chronically elevated IGF-I levels in active acromegaly
may be thus in part due the fact that less IGF-I is cleared from the
circulation by receptor-mediated mechanism. Moreover, high IGF-I le-
vels may change post-receptor signaling of the IGF-IR. Chronic IGF-I
stimulation may induce both internalization of the IGF-IR to the lyso-
some and degradation of insulin receptor substrates (IRS) proteins,
thereby the downregulating the Akt (=protein kinase B) pathway,
Fig. 2. Signaling pathways of the IGF-I receptor activated by IGF-I. Binding of IGF-I to the α subunit of the IGF-I receptor stimulates phosphorylation of tyrosine
residues of the β subunit which then induces phosphorylation of the Insulin Receptor Substrates (IRS 1–4) and SHC, which are docking proteins for activating of the
phosphatidylinositol 3-kinase (PI3K-Akt) pathway or the Ras/Raf/MEK/Erk pathway, respectively. The PI3K-Akt pathway is predominantly involved in metabolic
actions (glucose uptake, insulin sensitivity) whereas Ras/Raf/MEK/Erk pathway is predominantly involved in mitogenic effects (proliferation, growth).
Table 1
Metabolic effects of Growth Hormone (GH) and Insulin-like Growth Factor-I
(IGF-I).
GH IGF-I
Glucose uptake ↓ ↑
Insulin secretion ↑ ↓
Insulin sensitivity ↓ ↑
Lipolysis ↑ No effect
Protein synthesis ↑ No effect or ↑
Protein breakdown ↑ No effect




In healthy subjects metabolic effects of growth hormone (GH) and insulin-like
growth factor-I (IGF-I) are well in balance whereas in active (untreated) acro-
megaly insulin antagonistic effects of GH on glucose metabolism predominate
over IGF-I.
Healthy subjects Active acromegaly
GH levels Normal Increased
IGF-I levels Normal Increased
Negative feedback of IGF-I on GH secretion Normal Decreased
Insulin levels Normal Increased
glucose uptake Normal Decreased
Glycogenolysis Normal Increased
Gluconeogenesis Normal Increased
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which - as above discussed- is predominantly involved in metabolic
actions [20]. Recently it has been suggested that depletion of insulin
receptor substrate-1 (IRS-1) by prolonged IGF-I stimulation accelerates
IGF-IR endocytosis and thereby induces a shift from sustained to tran-
sient Akt signaling [20]. In the presence of a degree of IGF-IR resistance
of the pituitary (and hypothalamus), the IGF-I-induced feedback in-
hibition of GH secretion will be reduced, leading to increased GH and
IGF-I (Fig. 3B). When there is an IGF-I -induced degree of IGF-IR re-
sistance of the Akt pathway, high circulating IGF-I levels will have little
or reduced metabolic effects in muscles, but the high GH secretion as
consequence of the ineffective negative feedback of IGF-I on the pi-
tuitary gland, can lead to insulin resistance, hyperglycemia and hy-
perinsulinemia (Fig. 3B).
6.2. Insulin and IGF-I receptor signaling
Hyperinsulinemia and insulin resistance are important metabolic
hallmarks of acromegaly and they are strongly related to disease
Fig. 3. A. In healthy subjects growth hormone (GH) secreted by the
pituitary stimulates hepatic insulin-like growth factor-I (IGF-I) pro-
duction in the liver and release to the circulation. The circulating IGF-I
exerts a homeostatic feedback inhibition on GH secretion by the pi-
tuitary and hypothalamus. In addition, circulating IGF-I stimulates the
IGF-IR in muscles and other extrahepatic tissues. B In active (un-
treated) acromegaly there is usually overproduction of growth hor-
mone (GH) by a pituitary adenoma. As a consequence of excessive GH
secretion, circulating insulin-like growth factor-I (IGF-I) concentra-
tions are increased. Increased IGF-I levels per se may induce a degree
of IGF-IR resistance. In the presence of IGF-IR resistance at the pitui-
tary (and hypothalamus), the IGF-I-induced feedback inhibition of GH
secretion is ineffective, leading to increased circulating GH and IGF-I
levels. The high circulating IGF-I levels have also reduced effects in
muscles and other tissues through the (IGF-I -induced) (relative) IGF-IR
resistance. The high GH secretion can lead to insulin resistance, hy-
perglycemia and hyperinsulinemia. C Circulating levels of S-Klotho
levels in acromegaly depend on GH to a comparable extent as IGF-I.
When there is overproduction of growth hormone (GH) by a pituitary
adenoma Soluble Klotho (S-Klotho) levels are markedly increased in
active (untreated) acromegaly. Circulating S-Klotho is most likely of
renal origin, but the exact mechanism by which excess GH results in
increased release of kidney-derived S-klotho has not yet been eluci-
dated. S-Klotho is also a protein that has been reported to inhibit IGF-
IR signaling by inhibiting tyrosine phosphorylation and its downstream
signaling proteins (i.e. IRS) (see also Fig. 4). Thus increased S-Klotho
levels may induce a degree of IGF-IR resistance. As a consequence the
IGF-I-induced feedback inhibition of GH secretion at the pituitary (or
hypothalamus) level is reduced, leading to elevations in GH and IGF-I.
In addition, the increased circulating IGF-I levels have reduced effects
in muscles and other tissues through the S-Klotho-induced IGF-IR re-
sistance.
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activity [58]. Stimulation of the insulin receptor by insulin leads to a
decrease in intracellular IRS-1 levels [13]. Since IGF-I can also signal
through IRSeI, this may contribute to impaired IGF-I stimulated AKT
pathway [13]. In addition, it has been found that insulin after binding
to the insulin receptor may induce heterologous desensitization of the
signaling of the IGF-IR by downregulating β-arrestin-1 and inhibition of
IGF-I-stimulated MAP kinase phosphorylation [13]. Thus hyper-
insulinemia may reset the responsiveness of the IGF-IR and this may be
another mechanism responsible for (some degree of) IGF-IR resistance
at the post-receptor level in active acromegaly. It has been further
suggested that serine phosphorylation of IRS-1 is another mechanism of
the body to inhibit excess insulin- and IGF-I-mediated Akt1 signaling in
active acromegaly [12]. In favor of this latter possibility, it has been
found that elevated insulin and IGF-I in bGH giant mice increase serine
phosphorylation of IRS-1 in skeletal muscles and it has been suggested
that this may act to inhibit exaggerated glycolytic muscle growth in
environments of chronic GH/IGF-I excess [12].
It is thought that hyperinsulinemia, insulin resistance, glucose in-
tolerance and type 2 diabetes in active acromegaly are induced by the
prolonged exposure to high GH. For sure, hypersecretion of GH is an
important mediator of hyperinsulinemia and insulin resistance. Chronic
GH excess acts at several levels to block insulin actions and this induces
hyperglycaemia by increasing endogenous glucose production and de-
creasing peripheral glucose disposal in muscle [9]. Chronic GH excess
may induce a reduction in the number of insulin receptors at the cell
surface and an impairment of the kinase activity of the insulin receptors
[3,16]. Although the GH receptor lacks intrinsic tyrosine kinase ac-
tivity, it stimulates the activity of JAK-2, a tyrosine kinase that as-
sociates with the cytoplasmic domain of the activated GH receptor. It
has been suggested that activation of JAK-2 might result in tyrosine
phosphorylation of IRS-1 and possibly other proteins in the insulin
signaling pathway and thereby account for the insulin-like actions of
GH [51,61]. Chronic GH excess may lead to an increased phosphor-
ylation status of the insulin receptor and IRS-1 so that the insulin re-
ceptor and IRS-1 are maximally activated in the resting state [17,18].
The basal association of phosphatidylinositol3-kinase (PI-3 kinase) with
IRS-1, as well as PI-3 kinase activity, is also increased to maximal levels.
The maximal activation of the insulin receptor under basal conditions
has the effect of making the insulin receptor insensitive for further
stimulation by insulin [3,16]. As a consequence chronic exposure to GH
excess is associated with a decreased response to insulin stimulation in
terms of IRS-I phosphorylation and PI-3 kinase activity in skeletal
muscle [16]. In the adipocytes chronic GH treatment causes insulin
resistance by uncoupling activation of PI-3 kinase and its downstream
signals [53]. In the liver GH excess leads to chronic activation of the IR/
IRS-1/PI-3 kinase pathway, thus blocking insulin-induced activation
[16]. Thus despite hyperinsulinemia peripheral glucose uptake in
muscles and other insulin-dependent tissues is reduced whereas also the
ability of insulin to suppress gluconeogenesis is significantly reduced
[9]. A similar mechanism may be active for elevated circulating IGF-I
levels and the IGF-IR.
6.3. IGF-I receptor and Klotho
Klotho is a transmembrane protein mainly expressed in the kidneys,
choroid plexus and various endocrine-related tissues including the pi-
tuitary [46]. Klotho is an essential cofactor for the binding of fibroblast
growth factor 23 to its receptor, serving as a major regulator of phos-
phate metabolism [30]. It is also a potent inhibitor of the insulin and
IGF-I signaling [1,31,60]. In addition to its local effects Klotho can be
cleaved by two specific proteases (ADAM 10 and 17), shed and released
from the cell membrane to act as a circulating hormone (Soluble Klotho
(S-Klotho)) [29]. Insulin has been shown to activate both of these
proteases [8]. Currently GH and IGF-I are the biochemical markers used
to confirm active acromegaly and also for assessing the activity of ac-
romegaly [57]. However, recent data show that serum levels of S-
Klotho levels in acromegaly depend on GH to a comparable extent as
IGF-I. Excessive GH secretion results in markedly increased circulating
S-klotho levels in (untreated) active acromegaly [41] and they decrease
rapidly following adenoma removal suggesting a causal relation be-
tween GH-producing adenoma and high serum levels of S-Klotho in
active acromegaly [41,52]. Therefore circulating S-Klotho has been
introduced as a novel biomarker for the activity of GH-producing
adenoma [41]. Elevated circulating S-Klotho is most likely of renal
origin, but the exact mechanism by which excess GH results in in-
creased release of kidney-derived S-klotho has not yet been elucidated
[49]. It has been further found that S-Klotho can inhibit the activation
of the IGF-IR in a dose-dependent manner [31,59]. Thus elevated S-
Klotho levels in active acromegaly may contribute to (some degree of)
IGF-IR resistance [57]. As a consequence the IGF-I-induced feedback
inhibition of GH secretion at the pituitary (or hypothalamus) level is
reduced, leading to elevations in GH and IGF-I (Fig. 3C). Interestingly,
S-Klotho is a protein that has been reported also to inhibit IGF-IR and
insulin receptor signaling by inhibiting tyrosine phosphorylation of
both receptors and their downstream signaling proteins (i.e. IRS)
[31,60] (Fig. 4). Thus due to S-Klotho-induced IGF-IR resistance ele-
vated circulating IGF-I levels in active acromegaly have reduced effects
in muscles and other tissues.
6.4. Hyperglycemia and IGF-IR resistance
Chronic hyperglycemia probably plays also a role in the develop-
ment of IGF-IR resistance in active acromegaly. In cells exposed in vitro
to normal glucose, stimulation of the IGF-IR and its kinase results in
phosphorylation IRS-1 [38]. As above discussed, this is an important
adaptor protein that couples IGF-I stimulation of the IGF-IR to down-
stream activation of the PI-3 kinase signaling pathway. However, fol-
lowing exposure to hyperglycemia it has been reported that IGF-I re-
sponsiveness was reduced and IRS-I was down regulated [38].
7. GH hypersecretion and functional IGF-IR resistance in active
acromegaly
Persistent GH hypersecretion in active acromegaly together with
highly elevated IGF-I implies impaired negative feedback by IGF-I. In
support of this, it has been reported that negative feedback regulation is
greatly attenuated in active acromegaly [23]. The possibility that loss of
Fig. 4. Elevated Soluble Klotho (S-Klotho) levels in active acromegaly may
contribute to (some degree of) insulin-like growth factor-I (IGF-IR) resistance
and Insulin Receptor (IR) resistance at the receptor and post-receptor level.
Phosphorylation of the IGF-IR by IGF-I and phosphorylation of the IR by insulin
is reduced by S-Klotho. As a consequence Insulin Receptor Substrates (IRSs) and
the Akt pathway, which is predominantly involved in metabolic actions, will be
less stimulated.
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IGF-I feedback at the level of the pituitary/hypothalamus plays a pa-
thophysiological role in GH hypersecretion in acromegaly is supported
by in vitro data [23]. Furthermore, it has been suggested that a decrease
in number of IGF-IRs on somatotroph adenoma cells contributes to GH
hypersecretion in acromegaly or that alternatively, post-receptor ab-
normalities play a role in IGF-IR resistance [23]. Development of a
degree of IGF-IR resistance (mediated by elevated IGF-I, insulin and S-
Klotho levels) in active acromegaly may function as a safety valve of the
body that counteracts overstimulation by IGF-I of the IGF-IR in order to
avoid too large changes of the homeostasis [20].
8. Elevated IGF-I levels, IGF-IR resistance and effects on
metabolism in active acromegaly
As discussed above, compared to GH, IGF-I has divergent effects on
carbohydrate and lipid metabolism [37]. Most of the established me-
tabolic effects of GH may be classified as insulin-antagonistic: for ex-
ample, gluconeogenesis and lipolysis are stimulated by GH [21]. Most
metabolic effects of IGF-I can be classified as insulin-like [37]. For ex-
ample, IGF-I increases glucose uptake of muscles and inhibits gluco-
neogenesis. In addition, IGF-I can improve insulin sensitivity [9]. In fact
GH antagonizes the effects of IGF-I on glucose metabolism [37]. Al-
though IGF-I has been found to be 0.05–0.1 times as potent as insulin in
terms of stimulating glucose transport in vitro and inducing hypogly-
cemia, in vivo its concentration is in healthy subjects approximately
100 times higher compared to that of insulin [34,43,62]. In active
(untreated) acromegaly circulating IGF-I levels are usually >2 SD
above the upper limit of the normal range. Despite these elevated IGF-I
levels and the insulin-like effects of IGF-I, active acromegaly is char-
acterized by hyperinsulinemia, insulin resistance, high plasma glucose
concentrations and type 2 diabetes. However, in subjects without ac-
romegaly a potent glucose lowering effect is typically observed after
recombinant IGF-I administration, with improved insulin sensitivity
and lowering of insulin concentrations [37]. Even though this effect
may be (partly) mediated through stimulation of the insulin receptor,
experimental mice knockouts of the insulin receptor also show a potent
glucose lowering effect of IGF-I, indicative that the hypoglycemic effect
of IGF-I is mediated at least in part directly through the IGF-IR [15,37].
In addition, chronic IGF-I stimulation improves insulin sensitivity of
skeletal muscle and adipose tissue resulting in increased glucose
transport, increased glycogenesis and decreased lipolysis [22]. Ad-
ministration of IGF-I to subjects with type 2 diabetes results in a marked
enhancement of insulin sensitivity and a clear improvement of diabetic
control [10,39,40]. When Clemmons et al. previously studied patients
with active acromegaly and severe insulin resistance, they observed -as
expected- an improvement of insulin sensitivity and glucose control
after administration of the GH antagonist pegvisomant [44]. Although
insulin resistance that ensues acromegaly was at least partly improved
by lowering GH hypersecretion in this latter study, interestingly, a more
marked improvement in insulin sensitivity and glucose control was
observed when IGF-I was added to pegvisomant [44]. This finding does
not only suggest that IGF-I may have insulin-sensitizing actions on top
of and independent of its ability to suppress GH secretion, but it also
suggests that in untreated acromegaly endogenous markedly elevated
circulating IGF-I levels are insufficient to neutralize GH-mediated ef-
fects on insulin resistance [9]. Development of a degree of IGF-IR re-
sistance -initiated and sustained by high circulating IGF-I, insulin and S-
Klotho levels- could explain why in active acromegaly even IGF-I levels
>2SD above the normal range are not able and sufficient to overcome
the effects of GH on metabolism and to normalize insulin sensitivity and
glucose tolerance. When chronically elevated IGF-I, insulin and soluble
Klotho play a pathophysiological role in the development of IGF-IR
resistance in active acromegaly, sensitivity of the IGF-IR will be im-
proved by removing elevated circulating IGF-I, insulin and soluble
Klotho levels.
Normalization of circulating IGF-I is more frequently achieved by
monotherapy with the GH antagonist (pegvisomant) than by somatos-
tatin analogues [19,55]. Moreover, pegvisomant ameliorates all aspects
of glucose metabolism, while somatostatin analogues sometimes in-
crease plasma glucose levels [58]. At first glance this suggests, theo-
retically at least, that medical therapy with pegvisomant is better able
to reverse IGF-IR resistance in active acromegaly than somatostatin
analogues. However, further studies are needed to elucidate the exact
role of pegvisomant and somatostatin analogues on reversal of IGF-IR
resistance in active acromegaly.
In conclusion, active acromegaly is characterized by increased GH
secretion, elevated circulating IGF-I, insulin and S-Klotho levels. In this
paper the hypothesis is born that in active acromegaly chronically
elevated IGF-I, insulin and/or S-Klotho levels initiate and sustain a
degree of IGF-IR resistance. The development of a degree of IGF-IR
resistance (especially for metabolic functions of the IGF-IR) may help to
explain why in active acromegaly GH-mediated effects on glucose
metabolism predominate over IGF-I and are not prevented and counter-
regulated by elevated circulating levels of IGF-I. Further studies are
necessary to support this hypothesis.
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